UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K 

 

CURRENT REPORT

Pursuant to Section 13 or Section 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 18, 2024

 

BioNexus Gene Lab Corp.

(Exact name of registrant as specified in its charter)

 

 

Wyoming

 

333-229399

 

35-2604830

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

Unit 2, Level 10, Tower B, Avenue 3

The Vertical Business Suite II Bangar South

No. 8 Jalan Kerinchi

Kuala Lumpur, Malaysia

 

59200

(Address of Principal Executive Offices

 

Zip Code

 

Registrant’s telephone number, including area code: +1 307 241 6898

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

 

Securities registered or to be registered pursuant to Section 12(b) of the Act.

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, no par value

 

BGLC

 

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 7.01. Regulation FD Disclosure

 

On April 18, 2024, the Company issued the press release attached hereto as Exhibit 99.1.

 

The  information in this Item 7.01 of this Current Report shall not be deemed “filed” for any purpose,  including for the purposes  of  Section  18 of the  Exchange  Act,  or  otherwise  subject  to the liabilities of that Section.  The information in this Current Report on Form 8-K shall  not be deemed  incorporated  by  reference  into any  filing  under  the Securities  Act or the  Exchange  Act  regardless  of any general  incorporation language in such filing. The filing of this report and the furnishing of this information pursuant to Item 7.01 do not mean that such information is material or that disclosure of such information is required.

 

Item 8.01. Other Events.

 

As stated in the attached Press Release, the Company made a strategic investment through  its wholly owned subsidiary, MRNA Scientific Sdn Bhd, in Ascension Innovation Sdn Bhd, a Malaysian company.

 

Item 9.01. Financial Statements and Exhibits.

 

99.1

 

Press Release of the Company dated April 18, 2024.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document) 

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

BioNexus Gene Lab Corp.

 

 

 

 

Date: April 18, 2024

By:

/s/ Su-Leng Tan Lee

 

 

 

Name: Su-Leng Tan Lee

Title: Chief Executive Officer

 

 

3

 

nullv3.24.1.u1
Cover
Apr. 18, 2024
Cover [Abstract]  
Entity Registrant Name BioNexus Gene Lab Corp.
Entity Central Index Key 0001737523
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company true
Document Period End Date Apr. 18, 2024
Entity Ex Transition Period false
Entity File Number 333-229399
Entity Incorporation State Country Code WY
Entity Tax Identification Number 35-2604830
Entity Address Address Line 1 Unit 2, Level 10, Tower B, Avenue 3
Entity Address Address Line 2 The Vertical Business Suite II Bangar South
Entity Address Address Line 3 No. 8 Jalan Kerinchi
Entity Address City Or Town Kuala Lumpur
Entity Address Postal Zip Code 59200
City Area Code 307
Local Phone Number 241 6898
Security 12b Title Common Stock, no par value
Trading Symbol BGLC
Security Exchange Name NASDAQ
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Address Country MY
BioNexus Gene Lab (PK) (USOTC:BGLC)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more BioNexus Gene Lab (PK) Charts.
BioNexus Gene Lab (PK) (USOTC:BGLC)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more BioNexus Gene Lab (PK) Charts.